Product Description
Mechanisms of Action: Alkylating Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Molecular Templates
Company Location: AUSTIN TX 78729
Company CEO: Eric E. Poma
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pancreatic Cancer|Adenocarcinoma|Sarcoma
Phase 2: Sarcoma|Melanoma|Neuroendocrine Tumors|Glioblastoma|Pancreatic Cancer|Adenocarcinoma|Multiple Myeloma|Non-Small-Cell Lung Cancer|Prostate Cancer|Biliary Tract Cancer|Glioma|Astrocytoma
Phase 1: Liver Cancer|Kidney Cancer|Anorexia|Alopecia|Neuroendocrine Carcinoma|Renal Cell Carcinoma|Thrombocytopenia|Hypertension|Head and Neck Cancer|Neuroendocrine Tumors|Hypoxia|Esophageal Cancer|Anemia|Hepatocellular Carcinoma|Neutropenia|Diarrhea|Pancreatic Cancer|Gastrointestinal Stromal Tumors|Islet Cell Carcinoma|Gastrointestinal Cancer|Islet Cell Adenoma|Squamous Cell Carcinoma|Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Preleukemia|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Melanoma|Chronic Myeloid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Myelofibrosis|Prostate Cancer|Acute Lymphoid Leukemia|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SUNINET | P2 |
Completed |
Neuroendocrine Tumors |
2020-01-10 |
|
| CTRC 12-0105 | P2 |
Completed |
Glioblastoma |
2019-01-04 |
|
| TH-CR-417 | P1 |
Unknown status |
Squamous Cell Carcinoma|Prostate Cancer|Head and Neck Cancer|Melanoma|Pancreatic Cancer |
2019-01-01 |
|
| GETNE-1408 | P2 |
Completed |
Neuroendocrine Tumors|Pancreatic Cancer |
2018-05-31 |